Bristol Myers Squibb (NYSE: BMY) declared a quarterly dividend of $0.63 per share on its common stock.

The Board of Directors announced the payout, which is payable on November 2, 2026. Shareholders must be on record at the close of business on October 2, 2026 to receive the distribution.

Dividend Details

The company continues its mission to discover and deliver innovative medicines for serious diseases.

Bristol Myers Squibb (NYSE: BMY) reported positive Phase 2 results for its experimental cell therapy, arlocabtagene autoleucel (arlo-cel), in patients with quadruple-class exposed relapsed and refractory multiple myeloma.

The registrational QUINTESSENTIAL trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in this heavily pretreated population.

Trial Design and Population

The QUINTESSENTIAL trial (NCT06297226) evaluated arlo-cel, a potential first-in-class autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CAR T cell therapy. The therapy is designed for single-infusion administration.

The patient population consisted of adults with quadruple-class exposed RRMM who had received four or more prior lines of therapy. Quadruple-class exposure includes treatment with an immunomodulatory inhibitor, a proteasome inhibitor, an anti-CD38 therapy, and a BCMA-targeted therapy.

Clinical Outcomes

The study demonstrated a statistically significant and clinically meaningful overall response rate in patients with quadruple-class exposed RRMM after four or more prior lines of therapy. The trial also met the key secondary endpoint of complete response rate in this cohort.

Additionally, the study met the key secondary endpoints of overall response rate and complete response rate in patients with RRMM who were quadruple-class exposed after three or more prior lines of therapy.

Treatment Process and Safety

Arlo-cel operates as an autologous GPRC5D-directed CAR T cell therapy administered as a single infusion. The complete treatment process requires gathering T cells from the patient’s bloodstream, administering bridging therapy, manufacturing the specific CAR T cells, and applying lymphodepleting chemotherapy prior to the final infusion and safety monitoring period.

Trial investigators found the safety profile of arlo-cel remains consistent with other existing CAR T cell therapies and GPRC5D-targeting options used to treat multiple myeloma.

Next Steps

Bristol Myers Squibb intends to share comprehensive results from the QUINTESSENTIAL study during an upcoming medical meeting. Shares of Bristol-Myers Squibb were down 2.51% at $65.14 at the time of publication.